Barclays Maintains Overweight on Revolution Medicines, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson maintains an Overweight rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $52 to $54.
July 18, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Peter Lawson maintains an Overweight rating on Revolution Medicines and raises the price target from $52 to $54.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for RVMD.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100